Background and Aim
Home parenteral nutrition (HPN) provides nutritional support to intestinal failure patients. The aetiology of HPN-related metabolic bone disorders are multifactorial, related to underlying malnutrition and malabsorption, hypercalciuria and aluminium toxicity in earlier preparations1-3. Recent studies, however have indicated improvement in bone mineral density (BMD) after commencement of HPN, with high prevalence of low BMD at baseline1,4. This 20-year retrospective study reviews baseline DXA characteristics of HPN patients at a single-centre Intestinal Failure Service.
Material and Methods
All HPN patients at Westmead Hospital between 2000 and 2020 were retrospectively identified to obtain baseline DXA results and demographics (n=59). After excluding subjects who did not have a baseline DXA scan (GE Lunar) at Westmead Hospital, 22 patients were reviewed.
Results
Mean age was 48.6 years (18-84), with 12 males (54.5%) and 10 females (45.5%). 13/21 patients (61.9%) had Vitamin D deficiency (< 50nmol/L) at HPN commencement and 2 (9.1%) were on glucocorticoids. At baseline there was a significant burden of osteopenia (11/22, 50%) and osteoporosis (5/22, 22.7%) in this cohort. The broad categories for HPN indication were prolonged bowel rest (n=8) and inadequate absorption (n=14) related to various pathologies including short gut syndrome, gastroparesis and enterocutaneous fistula. These groups did not differ in their baseline bone density (1.05g/cm2 vs. 1.08g/cm2, p=0.84) or Vitamin D level (48.3nmol/L vs. 47.2nmol/L, p=0.93). Fracture rates could not be assessed. Of the six patients who died from underlying disease processes, baseline BMD T-score ≤-2.5 was not associated with death during the study period (p=0.68).
Conclusion
Metabolic bone disease is common in intestinal failure patients undergoing HPN, compounded by high rates of Vitamin D deficiency. This study highlights the importance of recognising this at-risk group with a need for longterm surveillance protocol with serial DXAs, consideration of Vitamin D replacement and/or early anti-resorptive therapy.